Abstract
Oral Squamous Cell Carcinoma (OSCC) is one of the most prevalent cancers in the world with the maximum number of cases reported from India. Poor survival rate associated with OSCC can be attributed to the non-availability of a biomarker, as one of the major reasons, leading to late presentation. Identification of an early diagnostic biomarker, which can also be used as a screening tool, will be helpful in reducing the disease morbidity and mortality. In this article, we report Parallel Reaction Monitoring (PRM) based validation of 12 candidate proteins, identified initially by tandem mass tag (TMT) based relative quantification of salivary proteins on LC-MS, in the saliva of Oral Squamous Cell Carcinoma (OSCC) cases (N=50) and healthy controls (N=49), AZGP1, AHSG, KRT6C, S100A7, S100A9, KLK1, BPIFB2, IGLL5, CORO1A, LACRT, LCN2 and PSAP. Heavy isotope labelled reference peptides were used to produce calibration curve and absolute quantification of proteins and resulting data were analyzed statistically using R. Salivary AHSG (p=0.0041**) and KRT6C (p=0.002**) were significantly upregulated in OSCC cases while AZGP1 (p=<0.0001***), KLK1 (p=0.006**) and BPIFB2 (p=0.0061**) were significantly downregulated. Multivariate logistic regression modelling resulted in a better risk prediction model consisting of AZGP1, AHSG and KRT6C with p value <0.0001***. Using this model ROC with an area under the curve of 82.2% was produced and sensitivity and specificity observed for this model was 78% and 73.5%, higher than any of the individual proteins. Positive and negative predictive values for the model were 76% and 75% respectively. We report a potential biomarker panel consisting of proteins AZGP1, AHSG and KRT6C for early diagnosis of OSCC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Department of Science and Technology- Science and Engineering Research Board (DST-SERB), New Delhi, (EMR/2016/003253) and Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India (71/2-Edu-15/128 & 71/2-Edu-16/4844-45). Indian Council of Medical Research (ICMR), New Delhi, India provided fellowship to Anu Jain [3/1/3/JRF-HRD-022 (10519)].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Ethics Committee at the Post Graduate Institute of Medical Education and Research, Chandigarh.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be available upon request from the authors.
